Top in endocrinology: Add-on PPI therapy, tirzepatide for type 2 diabetes
Click Here to Manage Email Alerts
Recent data showed that add-on proton pump inhibitor therapy was associated with a significant decrease in HbA1c and fasting blood glucose. However, it did not reduce the risk for incident diabetes.
A report on the data was the top story in endocrinology last week.
Another top story was about the SURPASS-2 study, which showed that 60% of participants who received the highest dose of the investigational drug tirzepatide achieved a composite endpoint of an HbA1c of 6.5% or lower and weight loss of 10% or greater without severe hypoglycemia, compared with 22% of participants who were assigned semaglutide.
Read these and more top stories in endocrinology below:
OTC antacids may modestly improve glucose in type 2 diabetes
Add-on proton pump inhibitor therapy improved glycemic markers among adults with type 2 diabetes, but did not alter risk for incident diabetes, according to a meta-analysis published in The Journal of Clinical Endocrinology & Metabolism. Read more.
SURPASS-2: Tirzepatide bests semaglutide in HbA1c reduction, weight loss
The investigational glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide led to significant and superior HbA1c and body weight reductions for adults with type 2 diabetes vs. semaglutide, SURPASS-2 study data show. Read more.
Does radioactive iodine treatment in hyperthyroidism increase risk for cancer?
Cari Kitahara, PhD, and Brian W. Kim, MD, debate the health risks of radioactive iodine therapy in the June issue of Endocrine Today. Read more.
Statement outlines strategies for recovery after exercise in type 1 diabetes
Adults with type 1 diabetes should take several key steps to optimize recovery after exercise, such as adjusting insulin dosing and protein and carbohydrate intake, and carefully monitoring blood glucose, according to a consensus statement. Read more.
More hospitalizations for new-onset type 2 diabetes in children during COVID-19
Hospitalizations for new-onset type 2 diabetes in children increased during the COVID-19 pandemic in 2020 compared with the same period in 2019, according to findings presented at the American Diabetes Association Scientific Sessions. Read more.